Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group.

Crofford LJ, Breyer MD, Strand CV, Rushitzka F, Brune K, Farkouh ME, Simon LS
J Rheumatol. 2006 33 (7): 1403-8

PMID: 16724374

The International COX-2 Study Group, a panel of independent physicians and scientists, convened January 28-30, 2005, in Washington, DC, to discuss the issues concerning the cardiovascular (CV) profile of coxibs. The purpose of the meeting was to review potential mechanisms by which inhibition of COX-2 by selective and nonselective NSAID could increase risk of CV events, to evaluate the similarities and differences between drugs based on mechanism and pharmacology, and to propose potential trial methodology to more definitively answer questions regarding cardiovascular risk.

MeSH Terms (9)

Arthritis, Rheumatoid Cardiovascular Diseases Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Evidence-Based Medicine Humans International Cooperation Membrane Proteins Rheumatology

Connections (1)

This publication is referenced by other Labnodes entities: